Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
32,913,612
-
Shares change
-
+5,390,836
-
Total reported value, excl. options
-
$62,907,536
-
Value change
-
+$9,179,739
-
Number of buys
-
40
-
Number of sells
-
-15
-
Price
-
$1.91
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q2 2020
63 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q2 2020.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32,913,612 shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (14,716,204 shares), PURA VIDA INVESTMENTS, LLC (5,983,724 shares), Blackcrane Capital, LLC (2,982,557 shares), BlackRock Inc. (2,598,615 shares), VANGUARD GROUP INC (1,813,185 shares), STATE STREET CORP (624,652 shares), NORTHERN TRUST CORP (494,032 shares), GEODE CAPITAL MANAGEMENT, LLC (477,589 shares), Phoenix Holdings Ltd. (292,275 shares), and Nuveen Asset Management, LLC (280,515 shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.